secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001193125-24-258006
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics cuts workforce 46%, extends cash runway into Q2 2026; Q3 net loss $7.3M
--------------------------------------------------------------------------------

- Net loss $7.3M for Q3 2024 vs $7.1M year ago; cash & securities $47.0M as of Sept 30.
- Organizational restructuring: closing Rockville research site, reducing workforce ~46%, focusing on SNS-101.
- SNS-101 Phase 1/2 dose expansion clinical data expected in H1 2025; enrollment ~50% complete.
- Appointed Josiah Craver as SVP Finance, principal financial and accounting officer in September.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524258006/0001193125-24-258006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524258006/d855965d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-258006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer